Clinical Trial

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Name: Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis — clinical trial record (NCT07250269)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-07-24

Trial Details

NCT Number	NCT07250269
Lead Sponsor	Gracell Biotechnologies (Shanghai) Co., Ltd. Collaborators: Suzhou Gracell Biotechnologies Co., Ltd.
Conditions	Relapsed/Refractory AL Amyloidosis
Enrollment	9 participants
Start Date	2025-10-29
Primary Completion	2028-11-24 (estimated)
Study Completion	2028-11-24 (estimated)
Updated on ClinicalTrials.gov	2026-07-23